

# The European Brain Council

An update on the 2015 – 2017 Research Project

*“Value of Treatment vs Cost of Non-Therapy for Brain Disorders in Europe – Case Study: Multiple Sclerosis”*

---

EMSP Conference, 17 May 2016

**Vinciane Quoidbach**

Public Health & Policy, Project Manager  
Value of Treatment Research Project  
European Brain Council



# EUROPEAN BRAIN COUNCIL

# Call To Action



## WHO WE ARE

The European Brain Council (EBC) is a non-profit organisation gathering patient associations, major brain-related societies as well as industries. Established in March 2002, its mission is to promote brain research in order to improve the quality of life of those living with brain disorders in Europe. 165 million Europeans are living with a brain disorder, causing a global cost (direct and indirect) exceeding 800 billion euros for the National Health budgets.

## EBC's main action areas



## NEWS

10.05.2016

Pianist Olga Bobrovnikova, EBC Ambassador, performed in favour of Multiple Sclerosis

Russian-born concert pianist Olga Bobrovnikova traveled from Belgium to take her seat at the piano,... [more](#)

## Cost counter (€)

Cost of Disorders of the Brain in Europe since January 2016

€ 285.558.793.760

<http://www.braincouncil.eu/>

# THE **VALUE OF TREATMENT** FOR BRAIN DISORDERS

A NEW VISION IN PROGRESS



## EBC Research Project 2015 – 2017

### Main Objectives:

- To assess the socio-economic impact of interventions (clinical practice), or the lack of thereof, and to provide evidence and tools that can assist policy makers and health actors in shaping effective policy responses to some of the most prevalent brain disorders, among which Multiple Sclerosis
- To build knowledge based on case study analysis conducted by a Working Group formed with Experts within the network of EBC member organisations (EAN) as well as other industry and patient representatives (EMSP), and supported by Academic Institutions and EBC



# Value of Treatment | What is ....

## Prevalence and costs of NDDS in Europe (2010)

| Disease     | Number of Subjects (million) | Cost per subject (€PPP) | Total cost (million €PPP) |
|-------------|------------------------------|-------------------------|---------------------------|
| Dementia    | 6.3                          | 16 584                  | 105 163                   |
| Parkinson's | 1.2                          | 11 153                  | 13 933                    |
| MS          | 0,54                         | 26 974                  | 14 559                    |

### Recent findings:

- 1) Non-medical costs and informal care** dominates the costs of MS.
- 2) All types of costs increase** with increasing severity of the disease. Also, similar **drop in QoL with increased disability.**
- 3) An integrated service delivery model** that is satisfying to patients and cost effective is to be recommended

Source: Costs and quality of life of patients with multiple sclerosis in Europe, Kobelt et al. (2006)

**Case study** will value **healthcare interventions** in comparison with the cost-burden of non-treatment

### Value of Treatment

|   |  |
|---|--|
| Cost analysis                                     | Value mapping (identification of current and potential values) |
| Cost impact analysis (with or without simulation) | Value optimizing initiatives                                   |
| Model calculations (health economics) incl. QALY  | New value creating initiatives (integrated care model)         |


### Combined methodology

**Policy White Paper and Scientific Publications of the Results in 2017**

# Case studies: research process

1. EBC Expert Workshop of Jan 8th & Kick off of Jan 27th

2. Joint Working Groups Meetings April 22nd & May 25th



## Focus on patient needs

| Patient Journey / Clinical pathway |            |           |                    |                    |                  |
|------------------------------------|------------|-----------|--------------------|--------------------|------------------|
| Collectors                         | Prevention | Screening | Early intervention | Disease management | End of Life Care |
| 1                                  |            |           |                    |                    |                  |
| 2                                  |            |           |                    |                    |                  |
| 3                                  |            |           |                    |                    |                  |
| 4                                  |            |           |                    |                    |                  |
| 5                                  |            |           |                    |                    |                  |
| 6                                  |            |           |                    |                    |                  |
| 7                                  |            |           |                    |                    |                  |
| 8                                  |            |           |                    |                    |                  |
| 9                                  |            |           |                    |                    |                  |
| 10                                 |            |           |                    |                    |                  |



# New treatment paradigm for MS

## Theoretical model: treat early and effectively

